Immune checkpoint inhibitor-related myocarditis in patients with lung cancer

医学 外科肿瘤学 心肌炎 肺癌 免疫检查点 癌症 免疫系统 肿瘤科 肺 内科学 免疫学 免疫疗法 癌症研究
作者
Wenli Cao,Sen Han,Panpan Zhang,Lan Mi,Yang Wang,Jun Nie,Ling Dai,Weiheng Hu,Jie Zhang,Xiaoling Chen,Xiangjuan Ma,Guangming Tian,Jindi Han,Di Wu,Jieran Long,Ziran Zhang,Qianyun Hao,Jian Fang,Kai Wang
出处
期刊:BMC Cancer [BioMed Central]
卷期号:25 (1): 685-685 被引量:7
标识
DOI:10.1186/s12885-025-13997-1
摘要

BACKGROUND: The clinical characteristics of immune checkpoint inhibitors (ICIs)-related myocarditis in lung cancer remains uncertain. The purpose of this study was to evaluate the incidence, clinical characteristics, risk factors, and prognosis of myocarditis in lung cancer patients treated with ICIs. Therefore, this study would enhance the understanding of immune related myocarditis in lung cancer population. METHODS: A total of 1004 patients were analyzed, among those who developed elevated serum creatine kinase isoenzyme, MB form (CK-MB) and/or high-sensitivity troponin I (hs-cTnI) with electrocardiographic or clinical symptoms after immunotherapy were enrolled in the myocarditis group. The same number of patients who had received immunotherapy but didn't develop myocarditis was randomly selected as the control group. Clinicopathologic features, risk factors, and prognostic factors were evaluated in this study. RESULTS: 66 patients (6.6%) developed ICIs-related myocarditis. In these patients, there were 60 case of possible myocarditis (90.9%), 5 probable myocarditis (7.6%), and 1 definite myocarditis (1.5%). The median time to the occurrence of myocarditis was 3.8 months. The median progression-free survival (PFS) for NSCLC and SCLC patients were 24.4 months and 13.0 months, while the median overall survival (OS) for NSCLC and SCLC patients were 43.3 months and 44.6 months. The grade of myocarditis (OR: 5.79; 95%CI: 1.14-29.41, P = 0.034), immunotherapy cycle (OR: 0.38; 95% CI: 0.16-0.92, P = 0.032), and combination of immune-related adverse events (irAEs) (OR: 3.63; 95% CI: 1.55-8.48, P = 0.003) were the influencing factors of PFS in NSCLC patients. In SCLC patients, the immunotherapy cycle was the influential factor for PFS (OR: 0.16; 95%CI: 0.04-0.61, P = 0.007) and OS (OS: 0.12; 95% CI: 0.03-0.48, P = 0.002). Anti-PD1 therapy (OR: 0.4, 95% CI: 0.13-0.97, P = 0.043) and age (OR: 0.36, 95% CI: 0.16-0.84, P = 0.018) might be the protective factors of myocarditis patients compared with the control group. CONCLUSIONS: The presentations of ICIs-related myocarditis in lung cancer are mainly possible myocarditis and probable myocarditis, which have a mild impact on the prognosis. More cycles of ICI treatment accompany the longer the PFS and OS, as a protective factor. Anti-PD1 therapy and older age may be protective factors for ICI-related myocarditis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
3秒前
drleslie完成签到 ,获得积分10
4秒前
Alexlovar发布了新的文献求助30
5秒前
5秒前
凯旋归来完成签到 ,获得积分10
5秒前
5秒前
6秒前
zhanzhanzhan发布了新的文献求助20
6秒前
7秒前
路小雨发布了新的文献求助10
8秒前
蒋莹萱完成签到 ,获得积分10
8秒前
简单的浩然完成签到,获得积分10
9秒前
9秒前
9秒前
wangyuu关注了科研通微信公众号
9秒前
活力孤菱完成签到,获得积分10
10秒前
nxdr发布了新的文献求助10
11秒前
英姑的应助被曾经的路灯采纳,获得10
11秒前
dxt发布了新的文献求助10
11秒前
卡皮巴拉完成签到 ,获得积分10
12秒前
GTR的我完成签到 ,获得积分10
12秒前
等风归发布了新的文献求助10
13秒前
Xy完成签到,获得积分10
13秒前
yu发布了新的文献求助10
13秒前
Akim的应助被饼饼采纳,获得10
14秒前
彭于晏的应助被unicornmed采纳,获得10
14秒前
复杂的悟空完成签到,获得积分10
14秒前
Alexlovar完成签到,获得积分20
15秒前
17秒前
Alicyclobacillus完成签到,获得积分10
18秒前
我爱科研科研爱我完成签到,获得积分10
21秒前
22秒前
小蘑菇的应助被陈小黑采纳,获得10
22秒前
23秒前
ly完成签到,获得积分10
23秒前
24秒前
ref:rain完成签到 ,获得积分10
25秒前
杨淼发布了新的文献求助10
26秒前
饼大王完成签到,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621